The product was approved in the EU, validating the therapy’s value and DLRC’s regulatory strategy. This approval was a key factor in the Sponsor’s subsequent acquisition in a multi-billion-dollar deal. DLRC continued to support the new sponsor with preparations for the Biologics License Application (BLA).
When the CEO launched a new company, they engaged DLRC to manage all aspects of regulatory affairs for their ongoing development project. This continuous collaboration showcases how strategic regulatory expertise can deliver substantial value throughout the drug development lifecycle, from initial clinical studies to approval and commercial success.